TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30219454

Group type: EXPERIMENTAL
Intervention: Jaungo applied twice a day for 3 weeks (treatment group 1)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Jaungo and placebo applied once a day for 3 weeks (treatment group 2)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo applied twice a day for 3 weeks (placebo group)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: All groups (including placebo)
Number of subjects: 28
Study: 26984485

Group type: EXPERIMENTAL
Intervention: Soya-maize-sorghum ready-to-use therapeutic food (SMS-RUTF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard peanut paste-based ready-to-use therapeutic food (P-RUTF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both RUTFs
Number of subjects: 0
Study: 24932147

Group type: EXPERIMENTAL
Intervention: Nasal expiratory positive airway pressure (NEPAP)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 23227307

Group type: EXPERIMENTAL
Intervention: Low-dose Tacrolimus (LD) with EC-MPS 720mg bid
Number of subjects: 292

Group type: COMPARATOR
Intervention: Standard-dose Tacrolimus (SD) with EC-MPS 720mg bid
Number of subjects: 292
Study: 20394511

Group type: EXPERIMENTAL
Intervention: Written and verbal information
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Written and verbal information with physical demonstration
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Physical demonstration
Number of subjects: 52

Group type: COMPARATOR
Intervention: Written and verbal information alone
Number of subjects: 52
Study: 18396035

Group type: EXPERIMENTAL
Intervention: 1 mg morphine + 5 mg ketamine/bolus (MK group)
Number of subjects: 57

Group type: COMPARATOR
Intervention: 1.5 mg morphine/bolus (MO group)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Subanaesthetic ketamine plus 2/3 the standard dose of morphine
Number of subjects: 57
Study: 15745926

Group type: EXPERIMENTAL
Intervention: Glucocorticoid treatment
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 6
Study: 12617614

Group type: EXPERIMENTAL
Intervention: Buckwheat honey (1.5 g/kg body weight)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corn syrup (1.5 g/kg body weight)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buckwheat honey (0.79 mg phenolic antioxidants per gram)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buckwheat honey (1.71 mg phenolic antioxidants per gram)
Number of subjects: 0
Study: 11067718

Group type: EXPERIMENTAL
Intervention: Pneumo 23° pneumococcal vaccine
Number of subjects: 26000

Group type: EXPERIMENTAL
Intervention: Older pneumococcal vaccines
Number of subjects: 26000
Study: 8846980

Group type: EXPERIMENTAL
Intervention: Specific inspiratory muscle training (SIMT) 3 times a week for 3 months
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 10
Study: 1317764

Group type: EXPERIMENTAL
Intervention: 750 mg of lithium carbonate
Number of subjects: 10

Group type: COMPARATOR
Intervention: 250 mg of lithium carbonate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3904373

Group type: EXPERIMENTAL
Intervention: Intravenous milrinone (25, 50, and 75 micrograms/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous milrinone
Number of subjects: 12
Study: 30340861

Group type: COMPARATOR
Intervention: Intralesional triamcinolone acetonide (TAC)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of 5-fluorouracil (5-FU) and triamcinolone acetonide (TAC)
Number of subjects: 120
Study: 29023174

Group type: EXPERIMENTAL
Intervention: SPRINT (4 × 30 second sprints separated by 4.5 minutes of active recovery)
Number of subjects: 16

Group type: COMPARATOR
Intervention: MOD (20 minutes at 65% peak power output)
Number of subjects: 16
Study: 26805720

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided foam sclerotherapy (UGFS)
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 798

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 798
Study: 24355576

Group type: EXPERIMENTAL
Intervention: Home-based smoking prevention program 'Smoke-free Kids' with five activity modules and one booster module after one year.
Number of subjects: 1478

Group type: COMPARATOR
Intervention: Control condition received a fact-based intervention only.
Number of subjects: 1478
Study: 22167716

Group type: EXPERIMENTAL
Intervention: Decremental test (DEC)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Final incremental test (INC(F))
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (INC)
Number of subjects: 26
Study: 20223557

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 5
Study: 15761201

Group type: EXPERIMENTAL
Intervention: High-flow oxygen therapy via facemask for 8 hours
Number of subjects: 16

Group type: COMPARATOR
Intervention: Room air (control)
Number of subjects: 16
Study: 10849219

Group type: EXPERIMENTAL
Intervention: Insulin infusion of 50 mU insulin/mL at 1 mL/h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin infusion of 200 mU insulin/mL at 1 mL/h
Number of subjects: 0
Study: 9380317

Group type: EXPERIMENTAL
Intervention: 21‐mg transdermal nicotine for 8 hours
Number of subjects: 14

Group type: COMPARATOR
Intervention: Smoking ad libitum for 8 hours
Number of subjects: 14
Study: 8230691

Group type: COMPARATOR
Intervention: 0.3 mg TNG solution (Solution group)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 0.3 mg TNG spray (Spray group)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study: 3083161

Group type: EXPERIMENTAL
Intervention: Face-to-face educational sessions with clinical pharmacists (2 sessions, average 18 minutes each)
Number of subjects: 435

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 435
Study: 29970639

Group type: EXPERIMENTAL
Intervention: Open face technique (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sand-blasting technique (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Preparing retentive grooves technique (Group C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 26458515

Group type: EXPERIMENTAL
Intervention: 40% VO2 peak exercise
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 60% VO2 peak exercise
Number of subjects: 27

Group type: COMPARATOR
Intervention: No-exercise seated control
Number of subjects: 27
Study: 23266839

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/day
Number of subjects: 365
Study: 20220746

Group type: COMPARATOR
Intervention: Acetaminophen-Placebo (AP)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Acetaminophen-Ondansetron (AO)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo-Placebo (PP)
Number of subjects: 134
Study: 18586925

Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiation therapy (combined modality treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Number of subjects: 0
Study: 16677798

Group type: EXPERIMENTAL
Intervention: Biotin 61.4 micromol/day for 28 days
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo for 28 days
Number of subjects: 33
Study: 12880507

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 61
Study: 11219367

Group type: EXPERIMENTAL
Intervention: Supervised injectable methadone maintenance treatment (MMT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral methadone maintenance treatment (MMT)
Number of subjects: 40
Study: 9379379

Group type: EXPERIMENTAL
Intervention: Topical timolol 0.5% gel (Timoptic XE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral, sustained‐release acetazolamide (Diamox Sequels)
Number of subjects: 60
Study: 1327628

Group type: EXPERIMENTAL
Intervention: Captopril (6.25 mg followed by 25 mg 2 h later)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2427842

Group type: EXPERIMENTAL
Intervention: Celiprolol 200 or 400 mg
Number of subjects: 58

Group type: COMPARATOR
Intervention: Propranolol 40 or 80 mg
Number of subjects: 58
Study: 29593018

Group type: EXPERIMENTAL
Intervention: Rhinothermy (35 L/min of 100% humidified air at 41°C via high flow nasal cannulae, 2 hours per day for up to 5 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rhinothermy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vitamin C (250 mg daily for 5 days)
Number of subjects: 30
Study: 27053325

Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg/day for 10 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 24950358

Group type: EXPERIMENTAL
Intervention: RTS,S+TRAP/AS02
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: TRAP/AS02
Number of subjects: 83

Group type: COMPARATOR
Intervention: Challenge control
Number of subjects: 83
Study: 22892455

Group type: EXPERIMENTAL
Intervention: rhGM‐CSF at 250 µg/m days 1‐14 of a 28‐day cycle (Group A)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: rhGM‐CSF at 250 µg 3 times a week continuously (Group B)
Number of subjects: 8
Study: 21095333

Group type: EXPERIMENTAL
Intervention: ACEi plus ARB (ramipril plus candesartan)
Number of subjects: 72

Group type: COMPARATOR
Intervention: ACEi plus β‐blockers (ramipril plus metoprolol)
Number of subjects: 72
Study: 18678789

Group type: EXPERIMENTAL
Intervention: Rasagiline 0.5 mg daily
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Rasagiline 1.0 mg daily
Number of subjects: 414

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 414
Study: 19330176

Group type: EXPERIMENTAL
Intervention: (99m)Tc‐DTPA in AS patients
Number of subjects: 21
Study: 15721575

Group type: EXPERIMENTAL
Intervention: Behavioral avoidance tests with a harmless tarantula
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral avoidance tests with a pen that had come in contact with the spider
Number of subjects: 0

Group type: COMPARATOR
Intervention: Behavioral avoidance tests with a clean pen
Number of subjects: 0
Study: 12413508

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 9598252

Group type: EXPERIMENTAL
Intervention: 0.1 mg.kg-1 rocuronium
Number of subjects: 42

Group type: COMPARATOR
Intervention: 0.1 mg.kg-1 atracurium
Number of subjects: 42

Group type: COMPARATOR
Intervention: 0.1 ml.kg-1 normal saline (placebo)
Number of subjects: 42
Study: 8181203

Group type: EXPERIMENTAL
Intervention: Computer-assisted heparin therapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: GUSTO heparin nomogram guidelines
Number of subjects: 51
Study: 3119776

Group type: EXPERIMENTAL
Intervention: RX77368 (thyrotrophin releasing hormone analogue), iv over 2 hours
Number of subjects: 25

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: RX77368
Number of subjects: 25
Study: 31933472

Group type: EXPERIMENTAL
Intervention: Domperidone 10 mg oral dose after 10 hours of fasting
Number of subjects: 36

Group type: COMPARATOR
Intervention: Domperidone 10 mg oral dose 30 minutes after a high-fat meal
Number of subjects: 36
Study: 29428486

Group type: EXPERIMENTAL
Intervention: Intra-articular knee implantation of 40 million autologous bone marrow-derived MSCs per joint
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 30
Study: 27244782

Group type: EXPERIMENTAL
Intervention: TAU plus brief individual CBT
Number of subjects: 212

Group type: COMPARATOR
Intervention: TAU (control)
Number of subjects: 212
Study: 23672806

Group type: EXPERIMENTAL
Intervention: Silmag(®)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bard(®)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Freka(®)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Kangaroo(®)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Wilson Cook(®)
Number of subjects: 100
Study: 22646853

Group type: EXPERIMENTAL
Intervention: Lavender olfactory stimulation (n = 73)
Number of subjects: 145
Study: 20946738

Group type: EXPERIMENTAL
Intervention: High levels of delinquency and violence exposure
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Lower delinquency but independent-living placement
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: African American adolescents
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: White adolescents not close to caregivers
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: White adolescents closer to caregivers with a history of psychological abuse
Number of subjects: 732
Study: 18719218

Group type: EXPERIMENTAL
Intervention: Oral appliance
Number of subjects: 103

Group type: COMPARATOR
Intervention: CPAP therapy
Number of subjects: 103
Study: 15879357

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Estrogen discontinuation after 28 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group of 38 healthy women matched for age and menopausal status
Number of subjects: 38
Study: 12578771

Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) application during silicone intubation (SI) at 0.2 mg/ml for 2 minutes before SI
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo application during silicone intubation (SI)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) application during silicone intubation (SI)
Number of subjects: 24
Study: 10475361

Group type: EXPERIMENTAL
Intervention: RT plus immediate androgen suppression (LHRH agonist)
Number of subjects: 139

Group type: COMPARATOR
Intervention: RT alone with hormonal manipulation at relapse
Number of subjects: 139
Study: 8607742

Group type: EXPERIMENTAL
Intervention: Portable performance-based assessment of balance and gait
Number of subjects: 24
Study: 1939527

Group type: EXPERIMENTAL
Intervention: 0.25 micrograms 1,25‐(OH)2D3, orally, twice per day for 6 months
Number of subjects: 98

Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 98
Study: 6110634

Group type: EXPERIMENTAL
Intervention: Lormetazepam
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 31987664

Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg/day
Number of subjects: 664

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/day
Number of subjects: 664
Study: 29681185

Group type: EXPERIMENTAL
Intervention: Cognitively-Based Compassion Training (CBCT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 56
Study: 27206047

Group type: EXPERIMENTAL
Intervention: Domestic Violence Enhanced Home Visitation Program (DOVE) intervention group, n = 124
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: DOVE treatment group
Number of subjects: 239

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 239
Study: 24794243

Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 1·5 once a week)
Number of subjects: 595

Group type: COMPARATOR
Intervention: No carboplatin
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 1·5 once a week) in triple-negative breast cancer
Number of subjects: 595

Group type: COMPARATOR
Intervention: No carboplatin in triple-negative breast cancer
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 1·5 once a week) in HER2-positive breast cancer
Number of subjects: 595

Group type: COMPARATOR
Intervention: No carboplatin in HER2-positive breast cancer
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Carboplatin
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 2·0 to 1·5)
Number of subjects: 595
Study: 23036218

Group type: EXPERIMENTAL
Intervention: XR‐NTX 380 mg
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 20603424

Group type: EXPERIMENTAL
Intervention: Reflective videotape-based feedback intervention tailored to risk groups
Number of subjects: 0
Study: 18570576

Group type: EXPERIMENTAL
Intervention: Ertapenem 1 g
Number of subjects: 672

Group type: COMPARATOR
Intervention: Cefotetan 2 g
Number of subjects: 672
Study: 15549344

Group type: EXPERIMENTAL
Intervention: COX-2 inhibitor celecoxib add on to risperidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risperidone alone
Number of subjects: 0
Study: 15037714

Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 10856310

Group type: EXPERIMENTAL
Intervention: Oxygen therapy (OT) at 4 l/min
Number of subjects: 25

Group type: COMPARATOR
Intervention: Air therapy (AT) at 4 l/min
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Oxygen therapy (OT) at baseline
Number of subjects: 25
Study: 9201614

Group type: EXPERIMENTAL
Intervention: Pippali Rasayana (PR) administered at a dose of 1 g p.o. three times daily for 15 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pippali Rasayana (PR)
Number of subjects: 50
Study: 1284487

Group type: EXPERIMENTAL
Intervention: Denopamine 10 mg and Midodrine HCl 4 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control subjects (not specified dosage or treatment)
Number of subjects: 6
Study: 3857627

Group type: EXPERIMENTAL
Intervention: Glucose infusion at 2 mg/kg of body weight per min
Number of subjects: 15
Study: 31218374

Group type: EXPERIMENTAL
Intervention: Flexed two-finger technique
Number of subjects: 42

Group type: COMPARATOR
Intervention: Two-thumb technique
Number of subjects: 42

Group type: COMPARATOR
Intervention: Two-finger technique
Number of subjects: 42
Study: 30465339

Group type: EXPERIMENTAL
Intervention: Universal adhesive treatment for 10 s (adult teeth)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Universal adhesive treatment for 20 s (adult teeth)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Universal adhesive treatment for 30 s (adult teeth)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Universal adhesive treatment for 10 s (youth teeth)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Universal adhesive treatment for 20 s (youth teeth)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Universal adhesive treatment for 30 s (youth teeth)
Number of subjects: 30
Study: 27540041

Group type: COMPARATOR
Intervention: Usual care (educational material and support for searching)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Feedback on high risk prescribing (quarterly feedback on five occasions)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Feedback plus behavioural change component
Number of subjects: 262
Study: 24130347

Group type: EXPERIMENTAL
Intervention: Antibiotics group (AG) - treated exclusively with antibiotics for 90 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Surgical group (SG) - underwent conservative surgery with postoperative antibiotic treatment for 10 days
Number of subjects: 24
Study: 23427386

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (performed three times/week from postoperative day 7 until postoperative day 21)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no acupuncture treatment)
Number of subjects: 80
Study: 19726173

Group type: EXPERIMENTAL
Intervention: Longer support intervention at the time of bronchoscopy
Number of subjects: 233

Group type: COMPARATOR
Intervention: Brief advice (control group)
Number of subjects: 233
Study: 18712641

Group type: EXPERIMENTAL
Intervention: Walking Impairment Questionnaire (WIQ)
Number of subjects: 105
Study: 15982136

Group type: EXPERIMENTAL
Intervention: Various child conduct problem interventions (specifics not provided)
Number of subjects: 514
Study: 12666511

Group type: EXPERIMENTAL
Intervention: Arthroscopic lavage or debridement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo arthroscopic procedure
Number of subjects: 0
Study: 9500747

Group type: EXPERIMENTAL
Intervention: TAA aqueous nasal spray 220 microg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: TAA aqueous nasal spray 440 microg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 7544732

Group type: EXPERIMENTAL
Intervention: Casodex (50 mg daily for 24 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 2653971

Group type: EXPERIMENTAL
Intervention: Calcitonin (415 pmol iv bolus followed by a 90 minute infusion to reach an overall dose of 62.25 pmol/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 8
Study: 338395

Group type: EXPERIMENTAL
Intervention: Benzydamine 3% cream
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 29783905

Group type: EXPERIMENTAL
Intervention: 1 mg lorazepam
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 2 mg lorazepam
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 27731820

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5µg/kg loading within 10 min and 0.5μg•kg‐1•h‐1 maintenance to the end of pneumoperitoneum, n=20, Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (normal saline, n=20, Group B)
Number of subjects: 40
Study: 24785342

Group type: EXPERIMENTAL
Intervention: Niferidil (10-30 μg/kg, intravenously, in 1-3 consecutive boluses at 15-minute intervals)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Niferidil
Number of subjects: 134
Study: 22563638

Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy (MST)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 256
Study: 20234144

Group type: EXPERIMENTAL
Intervention: Furosemide (1.0 mg/kg) after indomethacin administration
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (placebo after indomethacin administration)
Number of subjects: 68
Study: 18564322

Group type: EXPERIMENTAL
Intervention: Avoidant Personality Disorder (APD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Borderline Personality Disorder (BPD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both APD and BPD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher levels of depression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Borderline and avoidant personality pathology
Number of subjects: 0
Study: 15790982

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone 400 microg daily for 12 weeks
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone 2000 microg daily for 12 weeks
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (non-smokers receiving inhaled beclomethasone)
Number of subjects: 95